Get In Touch

Meningococcal Vaccine Market: Overview

Lately, growing prevalence of meningococcal meningitis has emerged as public health concerns. Although effective and cost-effective treatment options are available across the globe, the disease has taken toll on several lives. Further, its induction in children below 5 years of age has been leading to long-term neurological disorders in young children and infants.

Children belonging to age group below 5 years are found to be highly susceptible to the disease. Hence, 50% of all the reported cases is found in children belonging to aforementioned age group. Further, adolescents belonging to age group of 15-19 years category are found to be vulnerable to the disease.

Accounting the predominant ill-effects of the meningococcal meningitis on young population, key companies operating in the meningococcal vaccine landscape such as GlaxoSmithKline is focusing on development of the medicine to cater the requirement of population and control the contraction rate of the disease.

global meningococcal vaccines market

The vaccine market is witnessing favorable public-private alliances to support the development of vaccines at low cost and to curb the medical emergency status of the disease.

As per a report published by Transparency Market Research, the global meningococcal vaccines market is anticipated to witness expansion at a lucrative CAGR of 12.9% in the forecast period (2018-2026). In 2017, the market size was approximately equivalent to US $ 3.3 bn. As per the CAGR estimation given by market analyst, the market value is projected to reach approximately equal to US $ 9.9 bn by the end of 2026.

Government Immunizations Regulations Propelling Growth of Global Meningococcal Vaccine Market

Rising awareness regarding the vaccines due to awareness campaigns and education has resulted in growth in demand rate. The campaigns and awareness programs are particularly being driven by vaccine manufacturing companies, government bodies, and non-profit organizations. Large number of people are getting immunized against bacterial meningitis.

This is one of the prominent factors driving the global meningococcal vaccine market.

Further, government interventions, such as approval of legislations to enforce immunization regulations for school children up to a particular age is projected to fuel the market growth. Besides, government bodies are introducing strict regulation for sub-Saharan travelers and Hajj pilgrims are also anticipated to contribute to the global meningococcal vaccine market. The regulations have resulted in increase in demand for these vaccines from non-profit organizations.

Awareness Gap Regarding Meningococcal Meningitis and Vaccine Among Parents Resulting in Revenue Loss in Meningococcal Vaccine Market

On the other hand, in developing countries parents of young children and infants are still unaware of significance of the disease pathogenesis of meningococcal meningitis. Hence, they are deprived of meningococcal vaccination program initiated by government bodies.

This, in turn, has resulted in low adoption rate of meningococcal vaccines, specifically among toddlers and children.

Referring the recent statistics, among 5 parents, only 1 parent is aware of most common way in which children contracts meningococcal disease. The ratio accounts for 21% of the population. Further, half of the parents are unaware of the fact that there are different types of meningococcal bacteria strains. These bacterial strains may cause meningococcal meningitis.

Moreover, significant number of parents have no idea regarding specific vaccines included in the immunization schedule as defined by the government body in the respective country.

The awareness gap is one of the major factor leading to downturn of the growth trajectory of the meningococcal vaccines market.  As a result, revenue growth is also negatively impacted.

Immunization Programs and Awareness Programs in North America Contributing to Growth of Regional Market

 North America market holds prominent position in the global meningococcal vaccine market, in terms of revenue. Europe and North America have been witnessing significant reduction in number of the meningitis cases. Owing to rising awareness regarding the immunization therapy against meningitis and growing intervention by government bodies in legislations have resulted in controlling the disease in the region. In addition, awareness campaigns and immunizations programs are favoring growth of the meningococcal vaccine market.

As per a report published by the U.S. Centers for Disease Control and Prevention (CDC), nearly 1,000 t0 2,600 people are diagnosed with meningococcal disease in the U.S. annually. Meanwhile, 1,000 cases per 100, 000 population is found to contracted with the diseases every year.

Increasing patient pool in the North America region is providing wide growth prospects for the meningococcal vaccine market.

On the other hand, Asia Pacific regional market is estimated to scale at a significant rate during the forecast period. Recurrence of meningococcal disease outbreaks in recent years, growing focus on preventive measures against the disease, and growing population in the region are, conjointly, driving the regional meningococcal vaccine market.

Moreover, recent trends such as enrolment of pharmacists in the training programs is likely to boost the market. The training program is conducted by the New Zealand Ministry of Health.

Some of the key players operating in the global meningococcal vaccines market include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. among others

To mark their presence in the global market, companies are undertaking several organic and in-organic growth strategies. Merges and acquisitions, strategic alliances between companies and governing bodies, innovation in the existing product, diversification of product portfolio may result in growth of these companies in coming years.

Global Meningococcal Vaccines Market: Overview

This report analyzes the current and future scenario of the global meningococcal vaccines market. Advancements in healthcare, increase in awareness and education through various non-profit organizations, and a rise in patient awareness and health care expenditure are key factors that are projected to drive the global market during the forecast period. 

The global meningococcal vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. 

Global Meningococcal vaccines Market: Key Segments

The global meningococcal vaccines market has been segmented based on type, end-user, and region. In terms of type, the global market has been classified into polysaccharide vaccines, conjugate vaccines, combination vaccines, and Men B vaccines. The polysaccharide vaccines segment has been further sub-segmented into Menomune, Mencevax, NmVac4, and others. The conjugate vaccines segment has been further sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, and NmVac4-DT. The combination vaccines segment has been further split into MenHibrix, and Menitorix. The Men B vaccines segment has been further sub-segmented into Bexsero, and Trumenba. Based on end-user, the market has been classified into retail pharmacies, hospital pharmacies, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Meningococcal vaccines Market: Regional Outlook

In terms of region, the global meningococcal vaccines market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in the Report

The report also profiles major players in the global meningococcal vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. 

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global meningococcal vaccines market has been segmented as below:

Type

  • Polysaccharide Vaccines
    • Menomune
    • Mencevax
    • NmVac4
    • Others
  • Conjugate Vaccines
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
    • NmVac4-DT
  • Combination Vaccines
    • MenHibrix
    • Menitorix
  • Men B Vaccines
    • Bexsero
    • Trumenba

End-user

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others 

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

 

End-use Industry

  • Aerospace & Defense
  • Automotive
  • Consumer Electronics
  • Healthcare
  • Food & Beverages
  • Energy & Utility
  • Others (Including Telecommunication, Photonics, and Manufacturing)

Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
      1.1. Market Definition and Scope
      1.2. Market Segmentation
      1.3. Key Research Objectives
      1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global  Meningococcal Vaccines Market 

4. Market Overview
      4.1. Introduction
              4.1.1. Type Definition
              4.1.2. Industry Evolution / Developments
      4.2. Overview
      4.3. Market Dynamics
              4.3.1. Drivers
              4.3.2. Restraints
              4.3.3. Opportunities
              4.3.4. Market Trends 
      4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2016–2026
              4.4.1. Market Revenue Projections (US$ Mn)
      4.5. Porter’s Five Force Analysis

5. Market Outlook
      5.1.Pipeline Analysis 
      5.2. Epidemiology Of Meningococcal Disease
      5.3. Regulatory Scenario.

6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
      6.1. Introduction & Definition
      6.2. Key Findings / Developments
      6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              6.3.1. Polysaccharide
                        6.3.1.1. Menomune
                        6.3.1.2. Mencevax
                        6.3.1.3. NmVac4
                        6.3.1.4. Others
              6.3.2. Conjugate Vaccines 
                        6.3.2.1. Menactra
                        6.3.2.2. Menveo
                        6.3.2.3. NeisVac-C
                        6.3.2.4. Nimenrix
                        6.3.2.5. Meningitec
                        6.3.2.6. Menjugate
                        6.3.2.7. MenAfriVac
                        6.3.2.8. NmVac4-DT
              6.3.3. Combination Vaccines
                        6.3.3.1. MenHibrix
                        6.3.3.2. Menitorix
              6.3.4. Men B Vaccines
                        6.3.4.1. Bexsero
                        6.3.4.2. Trumenba 
              6.3.5. Others

7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user 
      7.1. Introduction & Definition
      7.2. Key Findings / Developments
      7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              7.3.1. Retail Pharmacies
              7.3.2. Hospital Pharmacies
              7.3.3. Others 
      7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user 

8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region/Sub-Region
      8.1. Key Findings
      8.2. Market Value Forecast, by Region
              8.2.1. North America 
              8.2.2. Europe 
              8.2.3. Asia-Pacific 
              8.2.4. Latin America 
              8.2.5. Middle East & Africa  
      8.3. Global Meningococcal Vaccines Market Attractiveness, by Region/Sub-Region

9. North America Meningococcal Vaccines Market Analysis and Forecast
      9.1. Introduction
              9.1.1. Key Findings
              9.1.1. Key Findings
      9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              9.2.1. Polysaccharide
                        9.2.1.1. Menomune
                        9.2.1.2. Mencevax
                        9.2.1.3. NmVac4
                        9.2.1.4. Others
              9.2.2. Conjugate Vaccines 
                        9.2.2.1. Menactra
                        9.2.2.2. Menveo
                        9.2.2.3. NeisVac-C
                        9.2.2.4. Nimenrix
                        9.2.2.5. Meningitec
                        9.2.2.6. Menjugate
                        9.2.2.7. MenAfriVac
                        9.2.2.8. NmVac4-DT
              9.2.3. Combination Vaccines
                        9.2.3.1. MenHibrix
                        9.2.3.2. Menitorix
              9.2.4. Men B Vaccines
                        9.2.4.1. Bexsero
                        9.2.4.2. Trumenba 
              9.2.5. Others
      9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              9.3.1. Retail Pharmacies
              9.3.2. Hospital Pharmacies
              9.3.3. Others 
      9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2016–2026
              9.4.1. U.S.
              9.4.2. Canada
      9.5. North America Meningococcal Vaccines Market Attractiveness Analysis 
              9.5.1. By Type 
              9.5.2. By End-user 
              9.5.3. By Country

10. Europe Meningococcal Vaccines Market Analysis and Forecast
      10.1. Introduction
              10.1.1. Key Findings
      10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              10.2.1. Polysaccharide
                        10.2.1.1. Menomune
                        10.2.1.2. Mencevax
                        10.2.1.3. NmVac4
                        10.2.1.4. Others
              10.2.2. Conjugate Vaccines 
                        10.2.2.1. Menactra
                        10.2.2.2. Menveo
                        10.2.2.3. NeisVac-C
                        10.2.2.4. Nimenrix
                        10.2.2.5. Meningitec
                        10.2.2.6. Menjugate
                        10.2.2.7. MenAfriVac
                        10.2.2.8. NmVac4-DT
              10.2.3. Combination Vaccines
                        10.2.3.1. MenHibrix
                        10.2.3.2. Menitorix
              10.2.4. Men B Vaccines
                        10.2.4.1. Bexsero
                        10.2.4.2. Trumenba 
              10.2.5. Others
      10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              10.3.1. Retail Pharmacies
              10.3.2. Hospital Pharmacies
              10.3.3. Others 
      10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016–2026
              10.4.1. Germany
              10.4.2. UK
              10.4.3. France
              10.4.4. Italy
              10.4.5. Spain
              10.4.6. Rest of Europe
      10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis 
              10.5.1. By Type 
              10.5.2. By End-user 
              10.5.3. By Country/Sub-Region

11. Asia-Pacific Meningococcal Vaccines Market Analysis and Forecast
      11.1. Introduction
              11.1.1. Key Findings
      11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              11.2.1. Polysaccharide
                        11.2.1.1. Menomune
                        11.2.1.2. Mencevax
                        11.2.1.3. NmVac4
                        11.2.1.4. Others
              11.2.2. Conjugate Vaccines 
                        11.2.2.1. Menactra
                        11.2.2.2. Menveo
                        11.2.2.3. NeisVac-C
                        11.2.2.4. Nimenrix
                        11.2.2.5. Meningitec
                        11.2.2.6. Menjugate
                        11.2.2.7. MenAfriVac
                        11.2.2.8. NmVac4-DT
              11.2.3. Combination Vaccines
                        11.2.3.1. MenHibrix
                        11.2.3.2. Menitorix
              11.2.4. Men B Vaccines
                        11.2.4.1. Bexsero
                        11.2.4.2. Trumenba 
              11.2.5. Others
      11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              11.3.1. Retail Pharmacies
              11.3.2. Hospital Pharmacies
              11.3.3. Others 
      11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016–2026
              11.4.1. Japan
              11.4.2. China
              11.4.3. India
              11.4.4. Australia & New Zealand
              11.4.5. Rest of Asia-Pacific 
      11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis 
              11.5.1. By Type 
              11.5.2. By End-user 
              11.5.3. By Country/Sub-Region

12. Latin America Meningococcal Vaccines Market Analysis and Forecast
      12.1. Introduction
              12.1.1. Key Findings
      12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              12.2.1. Polysaccharide
                        12.2.1.1. Menomune
                        12.2.1.2. Mencevax
                        12.2.1.3. NmVac4
                        12.2.1.4. Others
              12.2.2. Conjugate Vaccines 
                        12.2.2.1. Menactra
                        12.2.2.2. Menveo
                        12.2.2.3. NeisVac-C
                        12.2.2.4. Nimenrix
                        12.2.2.5. Meningitec
                        12.2.2.6. Menjugate
                        12.2.2.7. MenAfriVac
                        12.2.2.8. NmVac4-DT
              12.2.3. Combination Vaccines
                        12.2.3.1. MenHibrix
                        12.2.3.2. Menitorix
              12.2.4. Men B Vaccines
                        12.2.4.1. Bexsero
                        12.2.4.2. Trumenba 
              12.2.5. Others
      12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              12.3.1. Retail Pharmacies
              12.3.2. Hospital Pharmacies
              12.3.3. Others 
      12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016–2026
              12.4.1. Brazil
              12.4.2. Mexico
              12.4.3. Rest of Latin America
      12.5. Market Attractiveness Analysis 
              12.5.1. By Type 
              12.5.2. By End-user 
              12.5.3. By Country/Sub-Region

13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
      13.1. Introduction
              13.1.1. Key Findings
      13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2016–2026
              13.2.1. Polysaccharide
                        13.2.1.1. Menomune
                        13.2.1.2. Mencevax
                        13.2.1.3. NmVac4
                        13.2.1.4. Others
              13.2.2. Conjugate Vaccines 
                        13.2.2.1. Menactra
                        13.2.2.2. Menveo
                        13.2.2.3. NeisVac-C
                        13.2.2.4. Nimenrix
                        13.2.2.5. Meningitec
                        13.2.2.6. Menjugate
                        13.2.2.7. MenAfriVac
                        13.2.2.8. NmVac4-DT
              13.2.3. Combination Vaccines
                        13.2.3.1. MenHibrix
                        13.2.3.2. Menitorix
              13.2.4. Men B Vaccines
                        13.2.4.1. Bexsero
                        13.2.4.2. Trumenba 
              13.2.5. Others
      13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2016–2026
              13.3.1. Retail Pharmacies
              13.3.2. Hospital Pharmacies
              13.3.3. Others 
      13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016–2026
              13.4.1. GCC Countries
              13.4.2. Israel 
              13.4.3. South Africa
              13.4.4. Rest of Middle East & Africa
      13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis 
              13.5.1. By Type 
              13.5.2. By End-user 
              13.5.3. By Country/Sub-Region

14. Competition Landscape
      14.1. Market Player – Competition Matrix (By Tier and Size of companies)
      14.2. Competitive Business Strategies
      14.3. Company Profiles
              14.3.1. Neuron Biotech
                        14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.1.2. Financial Overview
                        14.3.1.3. Product Portfolio
                        14.3.1.4. SWOT Analysis 
                        14.3.1.5. Strategic Overview
              14.3.2. Baxter international
                        14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.2.2. Financial Overview
                        14.3.2.3. Product Portfolio
                        14.3.2.4. SWOT Analysis 
                        14.3.2.5. Strategic Overview
              14.3.3. Pfizer Inc.
                        14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.3.2. Financial Overview
                        14.3.3.3. Product Portfolio
                        14.3.3.4. SWOT Analysis 
                        14.3.3.5. Strategic Overview
              14.3.4. Novartis International
                        14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.4.2. Financial Overview
                        14.3.4.3. Product Portfolio
                        14.3.4.4. SWOT Analysis 
                        14.3.4.5. Strategic Overview
              14.3.5. Sanofi S.A
                        14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.5.2. Financial Overview
                        14.3.5.3. Product Portfolio
                        14.3.5.4. SWOT Analysis 
                        14.3.5.5. Strategic Overview
              14.3.6. JN-International Medical Corporation
                        14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.6.2. Financial Overview
                        14.3.6.3. Product Portfolio
                        14.3.6.4. SWOT Analysis 
                        14.3.6.5. Strategic Overview
              14.3.7. Biomed Pvt. Ltd.
                        14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.7.2. Financial Overview
                        14.3.7.3. Product Portfolio
                        14.3.7.4. SWOT Analysis 
                        14.3.7.5. Strategic Overview
              14.3.8. Serum Institute of India Ltd
                        14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.8.2. Financial Overview
                        14.3.8.3. Product Portfolio
                        14.3.8.4. SWOT Analysis 
                        14.3.8.5. Strategic Overview
              14.3.9. GlaxoSmithKline plc
                        14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                        14.3.9.2. Financial Overview
                        14.3.9.3. Product Portfolio
                        14.3.9.4. SWOT Analysis 
                        14.3.9.5. Strategic Overview

List of Tables

Table 01 Global Meningococcal Vaccine Market Pipeline Analysis
Table 02 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 03 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 04 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 05 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 06 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 07 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 08 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 10 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 11 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 12 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 13 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 14 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 15 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 16 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 18 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 19 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 20 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 21 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 22 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 23 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 24 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 25 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 26 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 27 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 28 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 29 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 30 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 31 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 32 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 33 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 34 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 35 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 36 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 37 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 38 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 39 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016–2026
Table 40 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016–2026
Table 41 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016–2026
Table 42 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016–2026
Table 43 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016–2026

List of Figures
 
Figure 01 Global Meningococcal Vaccines Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 02 Market Snapshot of Global Meningococcal Vaccines Market
Figure 03 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 04 Market Value Share, by Type, 2017
Figure 05 Market Value Share, by End-user, 2017
Figure 06 Market Value Share, by Region, 2017
Figure 07 Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2017 and 2026
Figure 08 Global Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 09 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by    Polysaccharide Vaccines, 2016–2026
Figure 10 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2016–2026
Figure 11 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2016–2026
Figure 12 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2016–2026
Figure 13 Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2017 and 2026
Figure 14 Global Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 15 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 16 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 17 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
Figure 18 Global Meningococcal Vaccines Market Value Share (%), by Region, 2017 and 2026
Figure 19 Global Meningococcal Vaccines Market Attractiveness, by Region, 2018–2026
Figure 20 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 21 North America Meningococcal Vaccines Market Value Share (%), by Country, 2017 and 2026
Figure 22 North America Meningococcal Vaccines Market Attractiveness, by Country, 2018–2026
Figure 23 North America Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
Figure 24 North America Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 25 North America Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
Figure 26 North America Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 27 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 28 Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 29 Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 30 Europe Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
Figure 31 Europe Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 32 Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
Figure 33 Europe Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 34 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 35 Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 36 Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 37 Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
Figure 38 Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 39 Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
Figure 40 Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 41 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 42 Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 43 Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44 Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
Figure 45 Latin America Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 46 Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
Figure 47 Latin America Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 48 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
Figure 49 Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 50 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 51 Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
Figure 52 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type, 2018–2026
Figure 53Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
Figure 54 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user, 2018–2026
Figure 55 Global Meningococcal Vaccines Market Share, by Company, 2018 
Figure 56 Baxter International, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
Figure 57 Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 58 Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
Figure 59 Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
Figure 60 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 61 Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 62 Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 63 Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2017
Figure 64 Sanofi S.A Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 65 Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2017
Figure 66 GlaxoSmithKline plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 67 GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Meningococcal Vaccines Market